Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
The gp63 gene of Leishmania major was transformed into the AroA- vaccine strain of Salmonella typhimurium (SL3261). The construct (SL3261-gp63), which stably expresses the gp63 Ag in vitro, was used to immunize CBA mice by the oral route. Spleen cells from mice inoculated with SL3261-gp63 developed...
Gespeichert in:
| Veröffentlicht in: | The Journal of immunology (1950) 1990-10, Vol.145 (7), p.2281-2285 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2285 |
|---|---|
| container_issue | 7 |
| container_start_page | 2281 |
| container_title | The Journal of immunology (1950) |
| container_volume | 145 |
| creator | Yang, DM Fairweather, N Button, LL McMaster, WR Kahl, LP Liew, FY |
| description | The gp63 gene of Leishmania major was transformed into the AroA- vaccine strain of Salmonella typhimurium (SL3261). The construct (SL3261-gp63), which stably expresses the gp63 Ag in vitro, was used to immunize CBA mice by the oral route. Spleen cells from mice inoculated with SL3261-gp63 developed antibody and proliferative T cell response to L. major. They did not express detectable delayed-type hypersensitivity reactivity. The activated T cells are mainly CD4+ and secrete IL-2 and IFN-gamma but no IL-4. The orally immunized mice developed significant resistance against a challenge L. major infection. We have, therefore, demonstrated the feasibility of oral vaccination against leishmaniasis and that the oral route of antigen delivery via the heterologous carrier may preferentially induce Th1 subsets of CD4+ cells. |
| doi_str_mv | 10.4049/jimmunol.145.7.2281 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79990113</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16797379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-90af77610b6291c7ed2561960df3bde99c17d881dc8594f89c4aa2683cfddac53</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhSMEKtPCEyAkL1B_FhnsxLHj5ajiT6rUBWVt3XFuJh7FTrCTDvNkvB4eZqi6Y2VZ9zvnXPtk2TtGl5xy9XFrnZv90C8Zr5ZyWRQ1e5EtWFXRXAgqXmYLSosiZ1LI19l5jFtKqaAFP8vOCsZ5xdUi-30foCffoXeDx74HMu3Hzro52NmR61UYVvkNeQRjrEeCv8aAMVq_IUAcbIdAerSxc-BtcolzaMEgGcMwofXkejOK8iZdscWAfkpMvyfWN7PBSB5Ih_2IgTBiUnIk4Juj1Ez2Ecnfx9lpT2AD1sfpWVS08U32qoU-4tvTeZH9-Pzp4fZrfnf_5dvt6i43vJRTrii0UgpG16JQzEhsikowJWjTlusGlTJMNnXNGlNXire1MhygEHVp2qYBU5UX2eXRN232c8Y4aWfjYV_wOMxRS6UUZaz8L8iEVLKUKoHlETRhiDH9jR6DdRD2mlF96FX_61WnXrXUh16T6v3Jfl47bJ40pyLT_MNpDtFA3wbwxsYnjFeFKOkBuzpind10OxtQR5daSaZM73a7Z4F_AEcPvy4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16797379</pqid></control><display><type>article</type><title>Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Yang, DM ; Fairweather, N ; Button, LL ; McMaster, WR ; Kahl, LP ; Liew, FY</creator><creatorcontrib>Yang, DM ; Fairweather, N ; Button, LL ; McMaster, WR ; Kahl, LP ; Liew, FY</creatorcontrib><description>The gp63 gene of Leishmania major was transformed into the AroA- vaccine strain of Salmonella typhimurium (SL3261). The construct (SL3261-gp63), which stably expresses the gp63 Ag in vitro, was used to immunize CBA mice by the oral route. Spleen cells from mice inoculated with SL3261-gp63 developed antibody and proliferative T cell response to L. major. They did not express detectable delayed-type hypersensitivity reactivity. The activated T cells are mainly CD4+ and secrete IL-2 and IFN-gamma but no IL-4. The orally immunized mice developed significant resistance against a challenge L. major infection. We have, therefore, demonstrated the feasibility of oral vaccination against leishmaniasis and that the oral route of antigen delivery via the heterologous carrier may preferentially induce Th1 subsets of CD4+ cells.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.145.7.2281</identifier><identifier>PMID: 2144549</identifier><identifier>CODEN: JOIMA3</identifier><language>eng</language><publisher>Bethesda, MD: Am Assoc Immnol</publisher><subject>Administration, Oral ; Animals ; Antibodies, Protozoan - analysis ; Antigens, Protozoan - immunology ; Biological and medical sciences ; Cloning, Molecular ; Experimental protozoal diseases and models ; Infectious diseases ; Leishmania major ; Leishmania tropica - immunology ; Leishmaniasis - parasitology ; Leishmaniasis - prevention & control ; Lymphocyte Activation ; Medical sciences ; Mice ; Mice, Inbred CBA ; Mutation ; Parasitic diseases ; Protozoal diseases ; Salmonella typhimurium ; Salmonella typhimurium - genetics ; Spleen - immunology ; T-Lymphocytes, Helper-Inducer - immunology ; Vaccines, Attenuated - administration & dosage ; Vaccines, Synthetic - administration & dosage</subject><ispartof>The Journal of immunology (1950), 1990-10, Vol.145 (7), p.2281-2285</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-90af77610b6291c7ed2561960df3bde99c17d881dc8594f89c4aa2683cfddac53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4526309$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2144549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, DM</creatorcontrib><creatorcontrib>Fairweather, N</creatorcontrib><creatorcontrib>Button, LL</creatorcontrib><creatorcontrib>McMaster, WR</creatorcontrib><creatorcontrib>Kahl, LP</creatorcontrib><creatorcontrib>Liew, FY</creatorcontrib><title>Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>The gp63 gene of Leishmania major was transformed into the AroA- vaccine strain of Salmonella typhimurium (SL3261). The construct (SL3261-gp63), which stably expresses the gp63 Ag in vitro, was used to immunize CBA mice by the oral route. Spleen cells from mice inoculated with SL3261-gp63 developed antibody and proliferative T cell response to L. major. They did not express detectable delayed-type hypersensitivity reactivity. The activated T cells are mainly CD4+ and secrete IL-2 and IFN-gamma but no IL-4. The orally immunized mice developed significant resistance against a challenge L. major infection. We have, therefore, demonstrated the feasibility of oral vaccination against leishmaniasis and that the oral route of antigen delivery via the heterologous carrier may preferentially induce Th1 subsets of CD4+ cells.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antibodies, Protozoan - analysis</subject><subject>Antigens, Protozoan - immunology</subject><subject>Biological and medical sciences</subject><subject>Cloning, Molecular</subject><subject>Experimental protozoal diseases and models</subject><subject>Infectious diseases</subject><subject>Leishmania major</subject><subject>Leishmania tropica - immunology</subject><subject>Leishmaniasis - parasitology</subject><subject>Leishmaniasis - prevention & control</subject><subject>Lymphocyte Activation</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred CBA</subject><subject>Mutation</subject><subject>Parasitic diseases</subject><subject>Protozoal diseases</subject><subject>Salmonella typhimurium</subject><subject>Salmonella typhimurium - genetics</subject><subject>Spleen - immunology</subject><subject>T-Lymphocytes, Helper-Inducer - immunology</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Synthetic - administration & dosage</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhSMEKtPCEyAkL1B_FhnsxLHj5ajiT6rUBWVt3XFuJh7FTrCTDvNkvB4eZqi6Y2VZ9zvnXPtk2TtGl5xy9XFrnZv90C8Zr5ZyWRQ1e5EtWFXRXAgqXmYLSosiZ1LI19l5jFtKqaAFP8vOCsZ5xdUi-30foCffoXeDx74HMu3Hzro52NmR61UYVvkNeQRjrEeCv8aAMVq_IUAcbIdAerSxc-BtcolzaMEgGcMwofXkejOK8iZdscWAfkpMvyfWN7PBSB5Ih_2IgTBiUnIk4Juj1Ez2Ecnfx9lpT2AD1sfpWVS08U32qoU-4tvTeZH9-Pzp4fZrfnf_5dvt6i43vJRTrii0UgpG16JQzEhsikowJWjTlusGlTJMNnXNGlNXire1MhygEHVp2qYBU5UX2eXRN232c8Y4aWfjYV_wOMxRS6UUZaz8L8iEVLKUKoHlETRhiDH9jR6DdRD2mlF96FX_61WnXrXUh16T6v3Jfl47bJ40pyLT_MNpDtFA3wbwxsYnjFeFKOkBuzpind10OxtQR5daSaZM73a7Z4F_AEcPvy4</recordid><startdate>19901001</startdate><enddate>19901001</enddate><creator>Yang, DM</creator><creator>Fairweather, N</creator><creator>Button, LL</creator><creator>McMaster, WR</creator><creator>Kahl, LP</creator><creator>Liew, FY</creator><general>Am Assoc Immnol</general><general>American Association of Immunologists</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19901001</creationdate><title>Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis</title><author>Yang, DM ; Fairweather, N ; Button, LL ; McMaster, WR ; Kahl, LP ; Liew, FY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-90af77610b6291c7ed2561960df3bde99c17d881dc8594f89c4aa2683cfddac53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antibodies, Protozoan - analysis</topic><topic>Antigens, Protozoan - immunology</topic><topic>Biological and medical sciences</topic><topic>Cloning, Molecular</topic><topic>Experimental protozoal diseases and models</topic><topic>Infectious diseases</topic><topic>Leishmania major</topic><topic>Leishmania tropica - immunology</topic><topic>Leishmaniasis - parasitology</topic><topic>Leishmaniasis - prevention & control</topic><topic>Lymphocyte Activation</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred CBA</topic><topic>Mutation</topic><topic>Parasitic diseases</topic><topic>Protozoal diseases</topic><topic>Salmonella typhimurium</topic><topic>Salmonella typhimurium - genetics</topic><topic>Spleen - immunology</topic><topic>T-Lymphocytes, Helper-Inducer - immunology</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Synthetic - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, DM</creatorcontrib><creatorcontrib>Fairweather, N</creatorcontrib><creatorcontrib>Button, LL</creatorcontrib><creatorcontrib>McMaster, WR</creatorcontrib><creatorcontrib>Kahl, LP</creatorcontrib><creatorcontrib>Liew, FY</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, DM</au><au>Fairweather, N</au><au>Button, LL</au><au>McMaster, WR</au><au>Kahl, LP</au><au>Liew, FY</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>1990-10-01</date><risdate>1990</risdate><volume>145</volume><issue>7</issue><spage>2281</spage><epage>2285</epage><pages>2281-2285</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><coden>JOIMA3</coden><abstract>The gp63 gene of Leishmania major was transformed into the AroA- vaccine strain of Salmonella typhimurium (SL3261). The construct (SL3261-gp63), which stably expresses the gp63 Ag in vitro, was used to immunize CBA mice by the oral route. Spleen cells from mice inoculated with SL3261-gp63 developed antibody and proliferative T cell response to L. major. They did not express detectable delayed-type hypersensitivity reactivity. The activated T cells are mainly CD4+ and secrete IL-2 and IFN-gamma but no IL-4. The orally immunized mice developed significant resistance against a challenge L. major infection. We have, therefore, demonstrated the feasibility of oral vaccination against leishmaniasis and that the oral route of antigen delivery via the heterologous carrier may preferentially induce Th1 subsets of CD4+ cells.</abstract><cop>Bethesda, MD</cop><pub>Am Assoc Immnol</pub><pmid>2144549</pmid><doi>10.4049/jimmunol.145.7.2281</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1767 |
| ispartof | The Journal of immunology (1950), 1990-10, Vol.145 (7), p.2281-2285 |
| issn | 0022-1767 1550-6606 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79990113 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Administration, Oral Animals Antibodies, Protozoan - analysis Antigens, Protozoan - immunology Biological and medical sciences Cloning, Molecular Experimental protozoal diseases and models Infectious diseases Leishmania major Leishmania tropica - immunology Leishmaniasis - parasitology Leishmaniasis - prevention & control Lymphocyte Activation Medical sciences Mice Mice, Inbred CBA Mutation Parasitic diseases Protozoal diseases Salmonella typhimurium Salmonella typhimurium - genetics Spleen - immunology T-Lymphocytes, Helper-Inducer - immunology Vaccines, Attenuated - administration & dosage Vaccines, Synthetic - administration & dosage |
| title | Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T14%3A26%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Salmonella%20typhimurium%20(AroA-)%20vaccine%20expressing%20a%20major%20leishmanial%20surface%20protein%20(gp63)%20preferentially%20induces%20T%20helper%201%20cells%20and%20protective%20immunity%20against%20leishmaniasis&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Yang,%20DM&rft.date=1990-10-01&rft.volume=145&rft.issue=7&rft.spage=2281&rft.epage=2285&rft.pages=2281-2285&rft.issn=0022-1767&rft.eissn=1550-6606&rft.coden=JOIMA3&rft_id=info:doi/10.4049/jimmunol.145.7.2281&rft_dat=%3Cproquest_cross%3E16797379%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16797379&rft_id=info:pmid/2144549&rfr_iscdi=true |